| breast cancer - HER2-positive | ||
| es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 2nd Line (L2) | |
| antibody–drug conjugate | ||
| trastuzumab deruxtecan | DESTINY Breast03 | |
| trastuzumab emtansine | KATHERINE Harbeck ... | EMILIA |
| trastuzumab emtasine plus endocrine therapy | Harbeck ... | |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
